--- title: "Clovertex Target of the Month (09/24): PTH1R" description: PTH1R is the September 2024 Clovertex target of the month following Septerna initiated a Phase 1 trial for SEP-786, an oral PTH1R agonist for hypoparathyroidism, and announced plans for an upcoming IPO. image: https://cryoduck.com/hubfs/PTH1R.png --- [Skip to content](https://cryoduck.com/blog/pth1r#main-content) [![cryoDuck Logo](https://cryoduck.com/hs-fs/hubfs/Home/horizontal%20light%20bg.png?width=300&height=66&name=horizontal%20light%20bg.png)](https://cryoduck.com) - [Home](https://cryoduck.com/) - [About](https://cryoduck.com/about) - [Blog](https://cryoduck.com/blog) - [Newsletter](https://cryoduck.com/newsletter) Open main navigation Close main navigation - [Home](https://cryoduck.com/) - [About](https://cryoduck.com/about) - [Blog](https://cryoduck.com/blog) - [Newsletter](https://cryoduck.com/newsletter) - [Contact us](https://cryoduck.com/contact) [Contact us](https://cryoduck.com/contact) Oct 13, 2024 12:36:25 PM # Clovertex Target of the Month (09/24): PTH1R ![Picture of Mazdak Radjainia](https://cryoduck.com/hs-fs/hubfs/PhotoSessions.nl-PWW_9643-bewerkt.jpg?width=50&name=PhotoSessions.nl-PWW_9643-bewerkt.jpg) [Mazdak Radjainia](https://cryoduck.com/blog/author/mazdak-radjainia) Share: [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://cryoduck.com/blog/pth1r) [Twitter icon](https://twitter.com/intent/tweet?url=https://cryoduck.com/blog/pth1r) [envelope icon](mailto:?body=https://cryoduck.com/blog/pth1r) We are pleased to announce that PTH1R (Parathyroid Hormone 1 Receptor) is Clovertex's Target of the Month for September! It's been an incredibly productive month for GPCR research, with multiple exciting developments in the field. Septerna recently announced the initiation of its Phase 1 clinical trial for SEP-786, a novel oral PTH1R agonist targeting hypoparathyroidism, marking their transition to a clinical-stage company. In addition, Septerna has announced plans for an upcoming IPO, aiming to fund the continued development of SEP-786 and its pipeline of GPCR-targeted therapies. Meanwhile, Superluminal Medicines closed a $120 million Series A funding round to accelerate its GPCR-targeted drug discovery efforts, and Confo Therapeutics published the first-ever cryo-EM structure of a GPCR-antibody agonist complex in *Nature Communications*, opening new possibilities for therapeutic interventions. September has been a busy month for GPCR advancements, underscoring the vast potential of targeting these receptors to develop innovative therapies. ![PTH1R](https://cryoduck.com/hs-fs/hubfs/PTH1R.png?width=1200&height=627&name=PTH1R.png) The [Protein Imager](https://academic.oup.com/bioinformatics/article/36/9/2909/5701652?guestAccessKey=69bb093e-3b30-4468-ada7-3ea6ff198636&login=false) rendering displays the cryo-EM structure of Human PTH1R in complex with PTH(1-34) and Gs (PDB entry [8FLQ](https://www.rcsb.org/structure/8FLQ)).   ## About Clovertex Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development. ## Useful links 1. [Septerna Announces Initiation of Phase 1 Clinical Trial with SEP-786](https://www.businesswire.com/news/home/20240927704554/en/Septerna-Announces-Initiation-of-Phase-1-Clinical-Trial-with-SEP-786-a-Novel-Oral-Small-Molecule-PTH1R-Agonist-for-the-Treatment-of-Hypoparathyroidism) 2. [Septerna files for IPO on strength of preclinical data](https://www.fiercebiotech.com/biotech/septerna-files-ipo-strength-preclinical-data-vision-expanding-druggable-gpcr-landscape) 3. [Superluminal Medicines Gets $120M to Take GPCR Drugs to Clinic](https://www.insideprecisionmedicine.com/topics/informatics/burn-rubber-superluminal-medicines-gets-120m-to-take-gpcr-drugs-to-clinic/) 4. [Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety](https://www.biospace.com/press-releases/confo-therapeutics-announces-publication-in-nature-communications-demonstrating-first-ever-structure-of-a-complex-between-an-antibody-based-agonist-and-a-class-a-gpcr-regulating-hunger-and-satiety) 5. Clovertex [website](http://clovertex.com) [Clovertex](https://cryoduck.com/blog/tag/clovertex), [target of the month](https://cryoduck.com/blog/tag/target-of-the-month) ## Related posts [![lgr5](https://cryoduck.com/hs-fs/hubfs/LGR5.png?height=200&name=LGR5.png)](https://cryoduck.com/blog/lgr5) [Clovertex](https://cryoduck.com/blog/tag/clovertex), [target of the month](https://cryoduck.com/blog/tag/target-of-the-month) ## [Clovertex Target of the Month (09/25): LGR5](https://cryoduck.com/blog/lgr5) ![Picture of Mazdak Radjainia](https://cryoduck.com/hs-fs/hubfs/PhotoSessions.nl-PWW_9643-bewerkt.jpg?width=50&name=PhotoSessions.nl-PWW_9643-bewerkt.jpg) [Mazdak Radjainia](https://cryoduck.com/blog/author/mazdak-radjainia) Oct 5, 2025 8:48:20 PM Clovertex’s September 2025 Target of the Month is LGR5, in light of Genmab’s announcement that it... [Read more](https://cryoduck.com/blog/lgr5) [![AAV9](https://cryoduck.com/hs-fs/hubfs/Target%20of%20the%20month-1.png?height=200&name=Target%20of%20the%20month-1.png)](https://cryoduck.com/blog/gpr61) [Clovertex](https://cryoduck.com/blog/tag/clovertex), [target of the month](https://cryoduck.com/blog/tag/target-of-the-month), [membrane protein](https://cryoduck.com/blog/tag/membrane-protein) ## [Clovertex Target of the Month (09/23): GPR61](https://cryoduck.com/blog/gpr61) ![Picture of Mazdak Radjainia](https://cryoduck.com/hs-fs/hubfs/PhotoSessions.nl-PWW_9643-bewerkt.jpg?width=50&name=PhotoSessions.nl-PWW_9643-bewerkt.jpg) [Mazdak Radjainia](https://cryoduck.com/blog/author/mazdak-radjainia) Sep 30, 2023 6:46:15 PM September's Clovertex Target of the Month is GPR61 following Pfizer's recent publication concerning... [Read more](https://cryoduck.com/blog/gpr61) [![btk](https://cryoduck.com/hs-fs/hubfs/BTK.png?height=200&name=BTK.png)](https://cryoduck.com/blog/btk) [Clovertex](https://cryoduck.com/blog/tag/clovertex), [target of the month](https://cryoduck.com/blog/tag/target-of-the-month) ## [Clovertex Target of the Month (01/24): BTK](https://cryoduck.com/blog/btk) ![Picture of Mazdak Radjainia](https://cryoduck.com/hs-fs/hubfs/PhotoSessions.nl-PWW_9643-bewerkt.jpg?width=50&name=PhotoSessions.nl-PWW_9643-bewerkt.jpg) [Mazdak Radjainia](https://cryoduck.com/blog/author/mazdak-radjainia) Feb 3, 2024 1:16:23 PM This January 2024, we're spotlighting Bruton's tyrosine kinase (BTK) as our Clovertex Target of the... [Read more](https://cryoduck.com/blog/btk) # Stay connected: Follow and engage with us Contact form or email Get in touch with us by completing the [contact form](https://cryoduck.com/contact) on our website or simply send us an email. ![Email](https://cryoduck.com/hs-fs/hubfs/Email.png?width=980&height=67&name=Email.png)   Bi-monthly newsletter Subscribe to our [bi-monthly newsletter](https://cryoduck.com/newsletter) to receive a summary of recent developments and highlights. The cryoDuck Blog Follow [the cryoDuck Blog](https://cryoduck.com/the-cryoduck-blog) for commentary on everything related to cryo-EM in drug discovery. LinkedIn group: Cryo-EM in pharma and biotech Join our [LinkedIn group community](https://www.linkedin.com/groups/8888430/) to network with industry professionals and engage in discussions pertaining to cryo-EM in industry.  LinkedIn company page Follow our [LinkedIn company page](https://www.linkedin.com/company/94199435/)  for company updates and latest contents. [![cryoDuck Logo](https://cryoduck.com/hs-fs/hubfs/Home/horizontal%20light%20bg.png?width=300&height=66&name=horizontal%20light%20bg.png "cryoDuck Logo")](https://cryoduck.com) 5615EC 86, Netherlands --- [Contact](https://cryoduck.com/contact) [Privacy and Cookies Policy](https://cryoduck.com/privacy-and-cookies-policies) [Terms and Conditions](https://cryoduck.com/terms-and-conditions) --- Copyright © 2026, cryoDuck B.V. Cookie Settings ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Mazdak Radjainia", "url" : "https://cryoduck.com/blog/author/mazdak-radjainia" }, "dateModified" : "2024-10-13T10:36:25.216Z", "datePublished" : "2024-10-13T10:36:25.000Z", "headline" : "Clovertex Target of the Month (09/24): PTH1R", "image" : [ "https://cryoduck.com/hubfs/PTH1R.png" ], "mainEntityOfPage" : { "@id" : "https://cryoduck.com/blog/pth1r", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://cryoduck.com/hubfs/Home/horizontal%20light%20bg.png" }, "name" : "cryoDuck B.V." } } ```